• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Pharmaceuticals

Convatec wins FDA approval for Parkinson’s treatment infusion tech

June 26, 2025 By Sean Whooley

ConvaTec

Convatec announced today that it received FDA approval for the delivery of a Parkinson’s disease therapy through its Neria Guard infusion set. The FDA approved apomorphine hydrochloride for subcutaneous infusion for the treatment of Parkinson’s. London-based Convatec’s Neria Guard set delivers the therapy under the skin (subcutaneous) as a continuous infusion via a small portable […]

Filed Under: Business/Financial News, Drug-Device Combinations, Food & Drug Administration (FDA), Neurological, Pharmaceuticals Tagged With: Convatec

Vaxess study highlights GLP-1 delivery with microarray patch

June 23, 2025 By Sean Whooley

Vaxess Technologies MIMIX vaccine patch

Vaxess Technologies today shared new preclinical data highlighting the capability of its drug delivery patch to deliver semaglutide. Semaglutide, a GLP-1 receptor agonist, is currently a treatment option for both diabetes and obesity management. Woburn, Massachusetts-based develops a microarray patch (MAP) designed to deliver drugs.  It features a soluble microarray with tips that gradually dissolve […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Pharmaceuticals, Technology Tagged With: ADA 2025, Vaxess Technologies

Lilly to submit once-weekly insulin for regulatory review this year following strong clinical results

June 22, 2025 By Sean Whooley

Eli Lilly

Eli Lilly (NYSE:LLY) today announced positive safety and efficacy data for its investigational once-weekly insulin efsitora alfa (efsitora). The QWINT-1, QWINT-3 and QWINT-4 Phase 3 clinical trials evaluated efsitora in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: ADA 2025, Eli Lilly, Eli Lilly & Co.

Flat Medical partners with Mercury Medical on smart syringe distribution

June 16, 2025 By Sean Whooley

Flat Medical EpiFaith Smart Syringe

Flat Medical announced today that it inked a dealership agreement with Mercury Medical to distribute its EpiFaith smart syringe in the U.S. Austin, Texas-based Flat designed EpiFaith to transform epidural procedures, according to a news release. It converts the tactile loss-of-resistance technique into an objective visual signal. The breakthrough technology enables anesthesia providers to identify […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Technology Tagged With: Flat Medical, Mercury Medical

Gore launches new plunger for prefilled syringes

June 3, 2025 By Sean Whooley

Gore ImProject 0.5_mL_Plunger_Photo (1)

W.L. Gore today announced the commercial launch of its new 0.5 mL silicone-free Gore ImProject syringe plunger. The new offering, designed specifically for prefilled syringes used in various applications, complements its 1 mL ImProject plunger. According to Gore, its uses extend to areas such as ophthalmic intravitreal injections. Newark, Delaware-based Gore says conventional prefilled syringe […]

Filed Under: Business/Financial News, Drug-Device Combinations, Optical/Ophthalmic, Pharmaceuticals Tagged With: W.L. Gore

Phillips Medisize fully integrates Vectura inhaled therapies into business

May 7, 2025 By Sean Whooley

Phillips Medisize Vectura

Phillips Medisize announced that it officially integrated Vectura into its business, expanding its capabilities in inhaled therapies. At the start of the year, the company completed its acquisition of Vectura from a subsidiary of cigarette maker Philip Morris. Vectura enables Phillips Medisize to offer a wider range of formulation, device design, combination product development and manufacturing […]

Filed Under: Business/Financial News, Drug-Device Combinations, Pharmaceuticals, Respiratory Tagged With: Phillips-Medisize, Vectura

Aptar reports positive adherence results with iPump dose software

April 14, 2025 By Sean Whooley

Aptar Digital health iPump (1) (1)

Aptar Digital Health today announced survey findings showcasing the impact of its iPump connected assistant for medication adherence. The SPEED survey looked at iPump’s effect on adherence to Stallergenes Greer’s sublingual liquid immunotherapy (SLIT). Stallergenes Greer will present findings at the CFA congress (Congrès Francophone d’Allergologie) in Paris this week. iPump, developed in conjunction with […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Patient Monitoring, Pharmaceuticals, Technology Tagged With: aptarpharma

Vaxess raises $9M to support drug delivery patch, GLP-1 work

April 9, 2025 By Sean Whooley

Vaxess Technologies MIMIX vaccine patch

Shelf-stable vaccine patch maker Vaxess Technologies announced today that it received an additional $9 million in funding. Participants in the latest funding round for Woburn, Massachusetts-based Vaxess included RA Capital Management and Engine Ventures. The company plans to use the funds to continue to advance its work in GLP-1 therapeutics and to expand manufacturing capabilities. It […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Funding Roundup, Pharmaceuticals Tagged With: Vaxess Technologies

Satio completes development, testing of remotely controllable, at-home intradermal drug delivery system

April 7, 2025 By Sean Whooley

Satio intradermal drug delivery system screenshot

Satio announced today that it completed a Small Business Innovation Research (SBIR) contract for its intradermal drug delivery system. The NIH’s Advanced Research Projects Agency for Health (ARPA-H) awarded Satio the $3.5 million in September 2023. This contract aimed to help the company develop SatioRx, its intradermal drug delivery device. The compact, inexpensive device features […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Technology Tagged With: Satio

Nasal vaccine devices: Design and regulatory need-to-knows

February 14, 2025 By Jim Hammerand

A photo of a nasal vaccine device spraying mist.

Nasal vaccine devices have the potential to offer more convenient and more effective protection against a variety of viruses. In 2024, the FDA approved a nasal spray as the first at-home influenza vaccination, allowing adults to vaccinate themselves or someone in their care without a needle jab or a trip to the pharmacy. Intranasal vaccines […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: aptarpharma

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Interim pages omitted …
  • Page 210
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS